PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Form 8-K May 22, 2013

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) May 21, 2013

Pacific Biosciences of California, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction 001-34899 (Commission 16-1590339 (IRS Employer

of incorporation)

File Number)

Identification No.)

Edgar Filing: PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - Form 8-K

1380 Willow Road

Menlo Park, California 94025

(Address of principal executive offices, including zip code)

(650) 521-8000

(Registrant s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):

" Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

" Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

" Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

" Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS

As previously disclosed on a Current Report on Form 8-K filed on March 7, 2013, Susan Siegel, a Class I director of Pacific Biosciences of California, Inc. (the Company) resigned from the Company s board of directors effective immediately prior to the Company s 2013 Annual Meeting of Stockholders (the Annual Meeting) on May 21, 2013.

ITEM 5.07. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

The Company held its Annual Meeting on May 21, 2013. The matters voted upon at the Annual Meeting and the results of such voting are set forth below.

Proposal 1: Election of Class III Directors

Name of Director	For	Withheld	Broker Non-Votes
William Ericson	36,242,444	2,993,400	13,981,648
David Botstein	36,967,215	2,268,629	13,981,648
Illians Estado and David Datatain sures dala alerted as Class III disectors			

William Ericson and David Botstein were duly elected as Class III directors.

Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm

51,750,515 1,420,920 46,057	For				Against	Ab	stain	В	roker N	on-Vot	es
	51,750,515				1,420,920	46	,057				

The appointment of Ernst & Young LLP as the Company s independent registered public accounting firm for the fiscal year ending December 31, 2013 was ratified.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

By:

Pacific Biosciences of California, Inc.

/s/ Brian B. Dow Brian B. Dow

Vice President and Principal Accounting Officer

Date: May 22, 2013